BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
June 17, 2024 07:05 ET
|
BioRestorative Therapies, Inc
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) --...
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
May 24, 2024 19:45 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 30, 2024 16:15 ET
|
BioRestorative Therapies, Inc
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity - MELVILLE, N.Y., April 30, 2024 (GLOBE...
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
April 16, 2024 07:45 ET
|
BioRestorative Therapies, Inc
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or...
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
April 03, 2024 16:38 ET
|
BioRestorative Therapies, Inc
- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the...
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
March 11, 2024 16:15 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
February 06, 2024 08:05 ET
|
BioRestorative Therapies, Inc
MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
February 05, 2024 07:30 ET
|
BioRestorative Therapies, Inc
— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05,...
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
February 01, 2024 07:30 ET
|
BioRestorative Therapies, Inc
— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — — Company to host webcasted conference call to review data on February 5, 2024 at...
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial
May 08, 2023 07:00 ET
|
BioRestorative Therapies, Inc
New York State’s largest health care provider will participate in BRTX’s clinical trial Expansive universe of patients and clinical sites from which to recruit high quality subjectsLeverage...